Investigating the Association between COVID-19 Prognosis and Demographic and Clinical Features, Underlying Diseases, and Drug and Supplement Use in Patients Hospitalized in Zabol, Iran: A Single-Center Retrospective Study

Document Type : Original Research

Authors
1 Department of Exercise Physiology, Faculty of Physical Education and Sport Sciences, Central Tehran Branch, Islamic Azad University, Tehran, Iran
2 Department of Pharmacology and Toxicology, Faculty of Pharmacy, Zabol University of Medical Sciences, Zabol, Iran
3 Department of Epidemiology & Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
4 Pharmacology Research Center, Zahedan University of Medical Sciences, Zahedan, Iran
Abstract
Backgrounds: The primary goal of this study was to identify the potential association between COVID-19 prognosis and demographic and clinical features, underlying diseases, and drug and supplement use in patients admitted to Amir al-Momenin hospital in Zabol.

Materials & Methods: This retrospective study surveyed the electronic health records of 848 COVID-19 patients hospitalized in a tertiary referral hospital in southeastern Iran from the beginning of the COVID-19 outbreak until the end of February 2021. Univariate and multiple analytical tests including unconditional and penalized logistic regressions were used for statistical analysis.

Findings: Out of a total of 848 patients, 371 (43.75%) patients were female, and 477 (56.25%) patients were male. Age, underlying pulmonary and cardiovascular diseases, and loss of consciousness predicted a higher mortality rate. On the contrary, a negative chest X-ray was associated with a lower risk of death.

Conclusion: Identifying predisposing factors of mortality in COVID-19 patients will help physicians provide more intensive care to those at higher risk of death by classifying patients based on risk factors and underlying diseases.

Keywords


1. Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579(7798):265-9. [DOI:10.1038/s41586-020-2008-3] [PMID]
Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270-3. [DOI:10.1038/s41586-020-2012-7]
Gorbalenya AE, Baker SC, Baric R, Groot RJ, Drosten C, Gulyaeva AA, et al. Severe acute respiratory syndrome-related coronavirus: The species and its viruses-a statement of the Coronavirus Study Group. BioRxiv. 2020. [DOI:10.1101/2020.02.07.937862]
Cunningham AC, Goh HP, Koh D. Treatment of COVID-19: Old tricks for new challenges. Crit Care. 2020;24(1):91. [DOI:10.1186/s13054-020-2818-6]
Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci Trends. 2020;14(1):69-71. [DOI:10.5582/bst.2020.01020] [PMID]
Ghaznavi H, Mohammadghasemipour Z, Shirvaliloo M, Momeni MK, Metanat M, Gorgani F, et al. Short-term celecoxib (celebrex) adjuvant therapy: A clinical trial study on COVID-19 patients. Inflammopharmacology. 2022;30(5):1645-57. [DOI:10.1007/s10787-022-01029-4]
Sheervalilou R, Shirvaliloo M, Dadashzadeh N, Shirvalilou S, Shahraki O, Pilehvar‐Soltanahmadi Y, et al. COVID‐19 under spotlight: A close look at the origin, transmission, diagnosis, and treatment of the 2019‐nCoV disease. J Cell Physiol. 2020;235(12):8873-924. [DOI:10.1002/jcp.29735] [PMID]
Sheervalilou R, Shirvaliloo M, Sargazi S, Bahari S, Saravani R, Shahraki J, et al. Convalescent blood: Current perspective on the efficacy of a legacy approach in COVID-19 treatment. Blood Purif. 2022;51(1):1-14. [DOI:10.1159/000513164] [PMID]
Sheahan TP, Sims AC, Graham RL, Menachery VD, Gralinski LE, Case JB, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. 2017;9(396):eaal3653. [DOI:10.1126/scitranslmed.aal3653] [PMID]
Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020;14(1):72-3. [DOI:10.5582/bst.2020.01047]
Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269-71. [DOI:10.1038/s41422-020-0282-0] [PMID]
Raoult D, Hsueh PR, Stefani S, Rolain JM. COVID-19 therapeutic and prevention. Int J Antimicrob Agents. 2020; 55(4):105937. [DOI:10.1016/j.ijantimicag.2020.105937] [PMID]
Shiraki K, Daikoku T. Favipiravir, an anti-influenza drug against life-threatening RNA virus infections. Pharmacol Ther. 2020;209:107512. [DOI:10.1016/j.pharmthera.2020.107512]
Amsden G. Anti-inflammatory effects of macrolides-an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions? J Antimicrob Chemother. 2005;55(1):10-21. [DOI:10.1093/jac/dkh519] [PMID]
Gautret P, Lagier JC, Parola P, Meddeb L, Mailhe M, Doudier B, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;56(1):105949. [DOI:10.1016/j.ijantimicag.2020.105949] [PMID]
Zhang C, Wu Z, Li JW, Zhao H, Wang GQ. Cytokine release syndrome (CRS) in severe COVID-19: Interleukin-6 receptor (IL-6R) antagonist tocilizumab may be the key to reduce mortality. Int J Antimicrob Agents. 2020;55(5):105954. [DOI:10.1016/j.ijantimicag.2020.105954] [PMID]
World Health Organization. Coronavirus disease 2019 (COVID-19): Situation report, 73. Geneva: World Health Organization; 2020.
Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. Jama. 2020;323(13):1239-42. [DOI:10.1001/jama.2020.2648] [PMID]
Jalili M, Payandemehr P, Saghaei A, Sari HN, Safikhani H, Kolivand P. Characteristics and mortality of hospitalized patients with COVID-19 in Iran: A national retrospective cohort study. Ann Intern Med. 2021;174(1):125-7. [DOI:10.7326/M20-2911] [PMID]
Arman A, Tajik M, Nazemipour M, Ahmadinejad Z, Shahrestanaki SK, Hazrati E, et al. Risk factors of developing critical conditions in Iranian patients with COVID-19. Glob Epidemiol. 2021;3:100046. [DOI:10.1016/j.gloepi.2020.100046]
Nikpouraghdam M, Farahani AJ, Alishiri G, Heydari S, Ebrahimnia M, Samadinia H, et al. Epidemiological characteristics of coronavirus disease 2019 (COVID-19) patients in Iran: A single center study. J Clin Virol. 2020;127:104378. [DOI:10.1016/j.jcv.2020.104378] [PMID]
Zali A, Gholamzadeh S, Mohammadi G, Looha MA, Akrami F, Zarean E, et al. Baseline characteristics and associated factors of mortality in COVID-19 patients; an analysis of 16000 cases in Tehran, Iran. Arch Acad Emerg Med. 2020;8(1):e70.
Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol. 2020;146(1):110-8. [DOI:10.1016/j.jaci.2020.04.006] [PMID]
Brusselaers N, Steadson D, Bjorklund K, Breland S, Stilhoff Sörensen J, Ewing A, et al. Evaluation of science advice during the COVID-19 pandemic in Sweden. Humanit Soc Sci Commun. 2022;9(1):91.
https://doi.org/10.1057/s41599-022-01254-w [DOI:10.1057/s41599-022-01097-5] [PMID]
Zheng F, Tang W, Li H, Huang Y, Xie Y, Zhou Z. Clinical characteristics of 161 cases of corona virus disease 2019 (COVID-19) in Changsha. Eur Rev Med Pharmacol Sci. 2020;24(6):3404-10.
Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, Villamizar-Peña R, Holguin-Rivera Y, Escalera-Antezana JP, et al. Clinical, laboratory, and imaging features of COVID-19: A systematic review and meta-analysis. Travel Med Infect Dis. 2020;34:101623. [DOI:10.1016/j.tmaid.2020.101623]
Chen J, Qi T, Liu L, Ling Y, Qian Z, Li T, et al. Clinical progression of patients with COVID-19 in Shanghai, China. J Infect. 2020;80(5):e1-6. [DOI:10.1016/j.jinf.2020.03.004] [PMID]
Du Y, Tu L, Zhu P, Mu M, Wang R, Yang P, et al. Clinical features of 85 fatal cases of COVID-19 from Wuhan. A retrospective observational study. Am J Respir Crit Care Med. 2020;201(11):1372-9. [DOI:10.1164/rccm.202003-0543OC] [PMID]
Drosten C, Günther S, Preiser W, van der Werf S, Brodt HR, Becker S, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med. 2003;348(20):1967-76. [DOI:10.1056/NEJMoa030747]
Garg S, Kim L, Whitaker M, O'Halloran A, Cummings C, Holstein R, et al. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019 - COVID-NET, 14 States, March 1-30, 2020. Morb Mortal Wkly Rep. 2020;69(15):458-64. [DOI:10.15585/mmwr.mm6915e3] [PMID]
Dadras O, SeyedAlinaghi S, Karimi A, Shamsabadi A, Qaderi K, Ramezani M, et al. COVID‐19 mortality and its predictors in the elderly: A systematic review. Health Sci Rep. 2022;5(3):e657. [DOI:10.1002/hsr2.657]
Garbern SC, Pryanka R, O'Reilly GM, Bills CB, Schultz M, Indi T, et al. A systematic review of acute and emergency care interventions for adolescents and adults with severe acute respiratory infections including COVID-19 in low- and middle-income countries. J Glob Health. 2022;12:05039. [DOI:10.7189/jogh.12.05039] [PMID]
Horby P, Lim WS, Emberson J, Mafham M, Bell J, Linsell L, et al. Effect of dexamethasone in hospitalized patients with COVID-19-preliminary report. MedRxiv. 2020:2020-06. [DOI:10.1101/2020.06.22.20137273]
Wu J, Liu J, Zhao X, Liu C, Wang W, Wang D, et al. Clinical characteristics of imported cases of coronavirus disease 2019 (COVID-19) in Jiangsu province: A multicenter descriptive study. Clin Infect Dis. 2020;71(15):706-12. [DOI:10.1093/cid/ciaa199] [PMID]
Bernheim A, Mei X, Huang M, Yang Y, Fayad ZA, Zhang N, et al. Chest CT findings in coronavirus disease-19 (COVID-19): Relationship to duration of infection. Radiology. 2020;295(3):685-91. [DOI:10.1148/radiol.2020200463]
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. Jama. 2020;323(11):1061-9. [DOI:10.1001/jama.2020.1585] [PMID]